{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:43:39Z","timestamp":1795085019074,"version":"4.10.2"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1097\/iae.0000000000001241","type":"journal-article","created":{"date-parts":[[2016,8,13]],"date-time":"2016-08-13T14:16:40Z","timestamp":1471097800000},"page":"710-717","source":"Crossref","is-referenced-by-count":89,"title":["COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY"],"prefix":"10.1097","volume":"37","author":[{"given":"Guoming","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Vakros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangjin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runsen","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"Gillbert","year":"2008","journal-title":"Early Hum Dev"},{"key":"R2-16-20210130","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1167\/iovs.08-2584","article-title":"Through the eyes of a child: understanding retinopathy through ROP: the Friedenwald lecture","volume":"49","author":"Smith","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R3-16-20210130","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat Med"},{"key":"R4-16-20210130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10792-010-9411-y","article-title":"Laser photocoagulation (810 nm diode) for threshold retinopathy of prematurity: a prospective randomized pilot study of treatment to ridge and a vascular retina versus vascular retina alone","volume":"31","author":"Uparkar","year":"2011","journal-title":"Int Ophthalmol"},{"key":"R5-16-20210130","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R6-16-20210130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitrealbevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R7-16-20210130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serumconcentrations of bevacizumab (avastin) and vascular endothelial growthfactor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R8-16-20210130","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","article-title":"Vascular endothelial growth factor plasma levels before and aftertreatment of neovascular age-related macular degeneration withbevacizumab or ranibizumab","volume":"90","author":"Carneiro","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"R9-16-20210130","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaophthalmol.2013.711","article-title":"Recurrence of retinopathy of prematurity following bevacizumab monotherapy: is it only the tip of the iceberg?","volume":"131","author":"Mireskandari","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R10-16-20210130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluoresceinangiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R11-16-20210130","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3928\/23258160-20150422-05","article-title":"Primary intravitreal ranibizumab for high-risk retinopathy of prematurity","volume":"46","author":"Baumal","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R12-16-20210130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12886-015-0001-7","article-title":"Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease","volume":"15","author":"Menke","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"R13-16-20210130","first-page":"132","article-title":"Guidelines for therapeutic use of oxygen and prevention and treatment of retinopathy in premature infants in Chinese.","volume":"15","year":"2004","journal-title":"Chin J Reprod Health"},{"key":"R14-16-20210130","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited.","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R15-16-20210130","first-page":"233","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R16-16-20210130","doi-asserted-by":"crossref","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","article-title":"Are we there yet? Bevacizumab therapy for retinopathy of prematurity","volume":"98","author":"Darlow","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R17-16-20210130","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaapos.2010.05.011","article-title":"Delayed-onset retinal detachmentafter an intravitreal injection of ranibizumab for zone 1plus retinopathy of prematurity","volume":"14","author":"Jang","year":"2010","journal-title":"J AAPOS"},{"key":"R18-16-20210130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/0974-620X.106103","article-title":"Intravitreal ranibizumab as salvagetherapy in an extremely low-birth-weight infant with rushtype retinopathy of prematurity","volume":"5","author":"Lin","year":"2012","journal-title":"Oman J Ophthalmol"},{"key":"R19-16-20210130","first-page":"6","article-title":"Effects of ranibizumab in zone I and zoneII retinopathy of prematurity patients [Chinese]","volume":"31","author":"Chen","year":"2015","journal-title":"Chin J Ocul Fundus Dis"},{"key":"R20-16-20210130","first-page":"10","article-title":"Effects of intravitrealranibizumab for the treatment of retinopathy of prematurity [Chinese]","volume":"31","author":"Yizuo","year":"2015","journal-title":"Chin J Ocul Fundus Dis"},{"key":"R21-16-20210130","first-page":"14","article-title":"The efficacy of laser photocoagulation and intravitrealranibizumab treatment of retinopathy of premature [Chinese]","volume":"31","author":"Sun","year":"2015","journal-title":"Chin J Ocul Fundus Dis"},{"key":"R22-16-20210130","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after Intravitreal Bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"R23-16-20210130","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaapos.2015.01.009","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"Isaac","year":"2015","journal-title":"J AAPOS"},{"key":"R24-16-20210130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ajo.2006.02.018","article-title":"Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease","volume":"142","author":"Flynn","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R25-16-20210130","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","article-title":"Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity","volume":"97","author":"Castellanos","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R26-16-20210130","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":"Serum concentrationsof vascular endothelial growth factor in an infant treated withranibizumab for retinopathy of prematurity","volume":"91","author":"Hoerster","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"R27-16-20210130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity afterranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000001241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T21:17:21Z","timestamp":1620940641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201704000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000001241","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726645046.793539822","asserted-by":"object"}]},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}